MY180772A - Novel therapeutic mirtazapine combinations for use in pain disorders - Google Patents

Novel therapeutic mirtazapine combinations for use in pain disorders

Info

Publication number
MY180772A
MY180772A MYPI2015703040A MYPI2015703040A MY180772A MY 180772 A MY180772 A MY 180772A MY PI2015703040 A MYPI2015703040 A MY PI2015703040A MY PI2015703040 A MYPI2015703040 A MY PI2015703040A MY 180772 A MY180772 A MY 180772A
Authority
MY
Malaysia
Prior art keywords
mirtazapine
combinations
novel therapeutic
pain disorders
inn
Prior art date
Application number
MYPI2015703040A
Other languages
English (en)
Inventor
Margarita Alekseevna Morozova
Allan Gerovich Beniashvili
Maksim Eduardovich Zapolsky
Original Assignee
Valenta Intellekt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valenta Intellekt Ltd filed Critical Valenta Intellekt Ltd
Publication of MY180772A publication Critical patent/MY180772A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MYPI2015703040A 2013-03-22 2014-03-17 Novel therapeutic mirtazapine combinations for use in pain disorders MY180772A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2013112747/15A RU2509560C1 (ru) 2013-03-22 2013-03-22 Новые терапевтические комбинации миртазапина для применения при болевых расстройствах

Publications (1)

Publication Number Publication Date
MY180772A true MY180772A (en) 2020-12-09

Family

ID=50279596

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015703040A MY180772A (en) 2013-03-22 2014-03-17 Novel therapeutic mirtazapine combinations for use in pain disorders

Country Status (7)

Country Link
CN (1) CN105209044B (fr)
EA (1) EA031906B1 (fr)
HK (1) HK1214156A1 (fr)
MY (1) MY180772A (fr)
RU (1) RU2509560C1 (fr)
UA (1) UA112726C2 (fr)
WO (1) WO2014148951A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ728036A (en) * 2014-01-21 2019-12-20 Wockhardt Ltd Pharmaceutical compositions comprising antibacterial agents
CN106243096B (zh) * 2016-07-29 2019-11-29 上海璃道医药科技有限公司 三环类药物的新用途
WO2018197932A1 (fr) * 2017-04-27 2018-11-01 Dr. Reddy's Laboratories Ltd. Compositions pharmaceutiques de kétorolac
RU2736713C1 (ru) * 2019-12-02 2020-11-19 Общество С Ограниченной Ответственностью "Валента - Интеллект" Комбинация миртазапина и тизанидина для применения при болевых расстройствах

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
US20080020076A1 (en) * 2006-07-21 2008-01-24 Khem Jhamandas Methods and Therapies for Potentiating a Therapeutic Action of an Alpha-2 Adrenergic Receptor Agonist and Inhibiting and/or Reversing Tolerance to Alpha-2 Adrenergic Receptor Agonists

Also Published As

Publication number Publication date
UA112726C2 (uk) 2016-10-10
CN105209044B (zh) 2017-08-15
RU2509560C1 (ru) 2014-03-20
WO2014148951A1 (fr) 2014-09-25
HK1214156A1 (zh) 2016-07-22
EA031906B1 (ru) 2019-03-29
CN105209044A (zh) 2015-12-30
EA201591603A1 (ru) 2016-01-29

Similar Documents

Publication Publication Date Title
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
MX2019003467A (es) Formulaciones y metodos para la administracion vaginal de antiprogestinas.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX360045B (es) Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MX370953B (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MX2015011775A (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12015501538A1 (en) Topical ocular analgesic agents
GB201115977D0 (en) Neurodevelopmental disorders
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
AR106220A1 (es) Conjugados homogéneos específicos de sitio con inhibidores de ksp
BR112015002384A8 (pt) combinações farmacêuticas compreendendo um inibidor de b-raf, um inibidor de egfr e, opcionalmente, um inibidor de pi3k-alfa, e seus usos".